Search filters

Filters
Clear All

Phase

  • 16
  • 19
  • 3
  • 1
  • 7
  • 6
  • 52
  • 5
  • 3
  • 49

Found 52 Solid Tumors trials

A listing of Solid Tumors medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Sort by:
18 years or above
All genders
Phase 1/2
Interventional
This study investigates the use of an investigational medication, a monoclonal antibody targeting Tumor Necrosis Factor Receptor 2 (TNFR2), in people with advanced malignancies. The purpose of the study is to evaluate the safety and tolerability of the investigational medication both alone and in combination with pembrolizumab, a type of …
18 years or above
All genders
Phase 1/2
Interventional
This study investigates an investigational medication for people with advanced cancers that are positive for the PRAME protein. The study aims to understand the safety and effectiveness of this investigational medication in adults who have a specific genetic marker called HLA-A*02:01 and PRAME-positive tumors.Participants in this study will receive the …
20 years - 99 years
All genders
Phase 1/2
Interventional
This study investigates a treatment for liver metastases from neuroendocrine tumors. It aims to find the best dose and safety of a hypoxia-activating agent combined with embolization, a procedure that blocks blood flow to cancer cells. The agent, administered directly into the liver's arteries, is evaluated using MRI scans based …
18 years or above
All genders
Phase 3
Interventional
This study investigates the effectiveness and safety of using Tumor Treating Fields (TTFields) in combination with pembrolizumab and platinum-based chemotherapy for treating metastatic non-small cell lung cancer (NSCLC). The purpose of this study is to assess how well patients survive overall and how long they live without the disease getting …
18 years or above
All genders
Phase 2
Interventional
This study investigates the effectiveness of adding an investigational medication to the standard treatment for patients with metastatic pancreatic cancer who have specific genetic mutations known as BRCA1 or BRCA2. The purpose of this study is to see if the combination of an investigational medication with olaparib, a targeted therapy …
18 years or above
All genders
Phase 3
Interventional
This study investigates the effectiveness of combining an investigational medication with chemotherapy to treat patients with certain types of sarcomas that have spread or cannot be surgically removed. The purpose of this study is to determine if adding the investigational medication to standard chemotherapy can improve outcomes for patients with …
18 years or above
All genders
Phase 3
Interventional
This study investigates how effective one year versus two years of maintenance therapy is for patients with advanced ovarian cancer that has BRCA1/2 mutations or is homologous recombination deficient (HRD+). The purpose is to compare the effects of using the investigational medication, olaparib, with or without an antiangiogenic agent, bevacizumab, …
18 years or above
All genders
Phase 2/3
Interventional
This study investigates non-small cell lung cancer. This study looks at how adding an investigational medication to the usual treatment affects patients with this condition.The study evaluates the safety and effectiveness of the investigational medication when used with standard treatments. It observes how well the treatment works and any side …
18 years or above
All genders
Phase 3
Interventional
This study investigates the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment for patients with locally advanced non-small cell lung cancer (NSCLC) that cannot be treated with surgery. The purpose is to see if SBRT, which uses precise radiation to target tumors, can improve outcomes when …
18 years or above
Female
Phase 3
Interventional
This study investigates the effectiveness of adding investigational medication combinations to the usual chemotherapy in patients with HER2 positive endometrial cancer. The investigational medications, which include monoclonal antibodies like trastuzumab and pertuzumab, target HER2 receptors on cancer cells to block signals for growth and potentially mark the cells for destruction …